109 related articles for article (PubMed ID: 22509921)
41. Bullous pemphigoid positive for anti-BP180 and anti-laminin 5 antibodies in a patient with graft-vs-host disease.
Izumi R; Fujimoto M; Yazawa N; Nakashima H; Asashima N; Watanabe R; Kuwano Y; Kurokawa M; Hashimoto T; Tamaki K
J Am Acad Dermatol; 2007 May; 56(5 Suppl):S94-7. PubMed ID: 17434049
[TBL] [Abstract][Full Text] [Related]
42. Autoantibodies to basement membrane proteins BP180 and BP230 are commonly detected in normal subjects by immunoblotting.
Desai N; Allen J; Ali I; Venning V; Wojnarowska F
Australas J Dermatol; 2008 Aug; 49(3):137-41. PubMed ID: 18638220
[TBL] [Abstract][Full Text] [Related]
43. Case of pemphigoid involving skin and mucous membrane with immunoglobulin G autoantibodies targeted to BP180 and laminin-332.
Hosoda S; Suzuki M; Komine M; Fujita E; Yamada T; Murata S; Koga H; Hashimoto T; Ohtsuki M
J Dermatol; 2013 Dec; 40(12):1067-8. PubMed ID: 24330181
[No Abstract] [Full Text] [Related]
44. [Pathological mechanisms and potential new therapies for autoimmune disease].
Shinkuma S; Shimizu H
Hokkaido Igaku Zasshi; 2009 May; 84(3):163-5. PubMed ID: 19507553
[No Abstract] [Full Text] [Related]
45. High serum anti-BP180 IgE levels correlate to prominent urticarial lesions in patients with bullous pemphigoid.
Cho YT; Liao SL; Wang LF; Chu CY
J Dermatol Sci; 2016 Jul; 83(1):78-80. PubMed ID: 27021592
[No Abstract] [Full Text] [Related]
46. Noncollagenous 16A domain of type XVII collagen-reactive CD4+ T cells play a pivotal role in the development of active disease in experimental bullous pemphigoid model.
Ujiie H; Shibaki A; Nishie W; Shinkuma S; Moriuchi R; Qiao H; Shimizu H
Clin Immunol; 2012 Feb; 142(2):167-75. PubMed ID: 22044750
[TBL] [Abstract][Full Text] [Related]
47. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain.
Hofmann S; Thoma-Uszynski S; Hunziker T; Bernard P; Koebnick C; Stauber A; Schuler G; Borradori L; Hertl M
J Invest Dermatol; 2002 Nov; 119(5):1065-73. PubMed ID: 12445194
[TBL] [Abstract][Full Text] [Related]
48. Relapse-associated autoantibodies to BP180 in a patient with anti-p200 pemphigoid.
Kasperkiewicz M; Hoppe U; Zillikens D; Schmidt E
Clin Exp Dermatol; 2010 Aug; 35(6):614-7. PubMed ID: 19874345
[TBL] [Abstract][Full Text] [Related]
49. A case of childhood bullous pemphigoid with IgG and IgA autoantibodies to various domains of BP180.
Osawa M; Ueda-Hayakawa I; Isei T; Yoshimura K; Fukuda S; Hashimoto T; Okamoto H
J Am Acad Dermatol; 2014 Jun; 70(6):e129-31. PubMed ID: 24831331
[No Abstract] [Full Text] [Related]
50. Conformational consequences of coupling bullous pemphigoid antigenic peptides to glutathione-S-transferase and their diagnostic significance.
Laczkó I; Vass E; Tóth GK; Marczinovits I; Kiss M; Husz S; Molnár J
J Pept Sci; 2000 Aug; 6(8):378-86. PubMed ID: 10969867
[TBL] [Abstract][Full Text] [Related]
51. IgE autoantibodies against the intracellular domain of BP180.
Dresow SK; Sitaru C; Recke A; Oostingh GJ; Zillikens D; Gibbs BF
Br J Dermatol; 2009 Feb; 160(2):429-32. PubMed ID: 18808416
[TBL] [Abstract][Full Text] [Related]
52. Anti-laminin γ1 pemphigoid associated with ulcerative colitis and psoriasis vulgaris showing autoantibodies to laminin γ1, type XVII collagen and laminin-332.
Akasaka E; Nakano H; Korekawa A; Fukui T; Kaneko T; Koga H; Hashimoto T; Sawamura D
Eur J Dermatol; 2015 Apr; 25(2):198-9. PubMed ID: 25787875
[No Abstract] [Full Text] [Related]
53. A case of bullous pemphigoid associated with autoantibodies targeting antigenic sites other than the NC16a domain of BP180.
Shinojima Y; Ochiai T; Kawamura A; Arakawa H; Fukuda K; Hashimoto T
Clin Exp Dermatol; 2005 Sep; 30(5):503-5. PubMed ID: 16045678
[TBL] [Abstract][Full Text] [Related]
54. Collagen XVII.
Has C; Kern JS
Dermatol Clin; 2010 Jan; 28(1):61-6. PubMed ID: 19945617
[TBL] [Abstract][Full Text] [Related]
55. [Anti-desmoglein 1 and 3 antibody, anti-BP180(NC16a) antibody, anti-BP230 antibody].
Amagai M
Nihon Rinsho; 2010 Jun; 68 Suppl 6():614-7. PubMed ID: 20942145
[No Abstract] [Full Text] [Related]
56. A case of vancomycin-induced linear IgA bullous dermatosis with circulating IgA antibodies to the NC16a domain of BP180.
Tashima S; Konishi K; Koga H; Hashimoto T
Int J Dermatol; 2014 Mar; 53(3):e207-9. PubMed ID: 23829415
[No Abstract] [Full Text] [Related]
57. Lichen planus pemphigoides: detection of anti-BP 180 antibodies by ELISA and immunoblotting tests.
Barnadas MA; Roé E; Dalmau J; Alomar A; Martínez L; Gelpí C
J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1360-1. PubMed ID: 20337815
[No Abstract] [Full Text] [Related]
58. Oral pemphigoid autoantibodies preferentially target BP180 ectodomain.
Calabresi V; Carrozzo M; Cozzani E; Arduino P; Bertolusso G; Tirone F; Parodi A; Zambruno G; Di Zenzo G
Clin Immunol; 2007 Feb; 122(2):207-13. PubMed ID: 17141573
[TBL] [Abstract][Full Text] [Related]
59. Acute blistering disease presenting IgG autoantibodies against NC16A and COOH-terminal domains of BP180 and laminin-332, with characteristic distribution of eruptions.
Kurashige Y; Minemura T; Nagatani T; Koga H; Hashimoto T
Eur J Dermatol; 2013; 23(1):109-10. PubMed ID: 23306276
[No Abstract] [Full Text] [Related]
60. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain.
Giudice GJ; Emery DJ; Zelickson BD; Anhalt GJ; Liu Z; Diaz LA
J Immunol; 1993 Nov; 151(10):5742-50. PubMed ID: 8228259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
